Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its ...

The lawsuit accused Bristol Myers of depriving holders of "contingent value rights" (CVR) an extra $9 per share in cash by ...

Fintel reports that on November 15, 2024, Wolfe Research initiated coverage of Bristol-Myers Squibb Company - Preferred ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) ...

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

Allogene is ceasing enrollment in a Phase I trial of cema-cel for patients with relapsed or refractory chronic lymphocytic ...

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

NEW YORK, Nov 14 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal ...